Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
ConditionRheumatoid Arthritis (RA)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Princesse Grace
About this trial
The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response.
The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.
Eligibility criteria
Qualifiers
Patient aged over 18 years
Patient with Rheumatoid Arthritis according to the 2010 ACR/EULAR criteria
Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations
Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure.
Disqualifiers
No contraindication to a bDMARD
Not stable dose of corticosteroids in the 4 weeks preceding enrollment
Not stable dose of maintenance therapy (methotrexate, leflunomide, hydroxychloroquine, cyclosporine, gold salts) in the 4 weeks preceding enrollment
Prior treatment with a JAK inhibitor
Trial design
Treatments tested in this trial
- Not listed
Trial groups
90 Participants
are grouped into 2 trial groupsLocations
1Centre Hospitalier Princesse Grace98000, Monaco Monaco
Sponsors and collaborators
Centre Hospitalier Princesse Grace
Lead sponsor
Source ClinicalTrials.gov